| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CERE | Common Stock | Options Exercise | +14.3K | +50% | 42.8K | Sep 24, 2021 | Direct | F1 | ||
| holding | CERE | Common Stock | 633K | Sep 24, 2021 | See footnote | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CERE | Restricted Stock Units | Options Exercise | $0 | -14.3K | -100% | $0.00 | 0 | Sep 24, 2021 | Common Stock | 14.3K | Direct | F1, F3 |
| Id | Content |
|---|---|
| F1 | The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. |
| F2 | Shares held by Novalis LifeSciences Investments I, L.P., or Novalis LifeSciences. Marijn Dekkers, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. |
| F3 | 14,270 RSUs vested on September 24, 2021, the third anniversary of the vesting commencement date of September 24, 2018. |